These bunches in nature often remind me of ball and spoke chemical structures

One of the hot topics at the recent AACR meeting was undoubtedly protein degradation, including the PROTACs from Arvinas, monoDACs from C4 Therapeutics and IRAKIMiD from Kymera, not to mention a bunch of other targets.

Certainly there’s plenty of science to review for a new mini-series with a lot to unpack from each.

In the first part of this new series we focus on Arvinas and what we can learn from the details provided, plus an in-depth expert interview.

To learn more about our ongoing post AACR21 meeting analysis and expert interviews to get a heads up on key oncology commentary and insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

Posted by